Women’s Health Strategy for England

Debate between Carolyn Harris and Steve Barclay

Wednesday 20th July 2022 Commons Chamber

[Steve Barclay]

The work on this strategy was done before I arrived in the Department, so it was down to my right hon. Friend and to the Minister of State, my hon. Friend the Member for Lewes (Maria Caulfield). It is great to have this opportunity to pay tribute to my predecessor for all that he did to drive this agenda forward. He is absolutely right about the importance of training and early diagnosis. That is why addressing the issue of fragmented services is so important. As a respondent said, where women raise concerns, they often feel like a lone voice in the wind—that was a phrase in the strategy that really resonated with me. Having hubs, centres of excellence and the ability to look at that data and identify it early, alongside the other initiatives in which he played a major role as Secretary of State, such as the diagnostic hubs, are all a key part of the delivery of this strategy.

[Carolyn Harris (Swansea East) (Lab)]

I rise to speak specifically on the menopause services included in the strategy. As co-chair of the Government menopause taskforce, I broadly welcome the strategy but feel that it falls short in some places.

Although better menopause training for doctors of the future is essential, there is not much in the strategy now in terms of upskilling GPs or prescriber medics, such as pharmacists or women’s health nurses. With only 14% of women accessing hormone replacement therapy and menopause care, through medical lack of awareness in diagnosing and prescribing, training medical professionals of the future does nothing for women today.

With 50% of women not even discussing their symptoms, we need a public awareness campaign—outside the one being run by the media and by grassroots and celebrity activists—to ensure that all women get the memo, as it were. We need a commitment to a national formulary for HRT to end postcode lottery in quality, quantity and availability of body identical hormone replacement therapy—I emphasise body identical.

As for HRT costs, I am delighted that my private Member’s Bill that I negotiated with the Government last October now appears as part of the strategy, but I am bitterly disappointed that the timeframe for that once annual charge is delayed until April 2023— 18 months after it was promised—demonstrating to me a lack of urgency in dealing with women’s health issues that affect 51% of the population.

As we are talking about delays and women not being listened to, I am still waiting on responses to six letters to either this Secretary of State or to his predecessor dating back to 5 May asking to discuss all the issues that I have raised today. I would be grateful to have a meeting to discuss them further.

[Steve Barclay]

The hon. Lady says that she is not being listened to, but my understanding is that she is co-chair of the menopause taskforce, which has been set up to look at these issues. Indeed, she has also had meetings with officials on the subject of HRT. It is slightly remiss of her to suggest that she is not being listened to when Health Department officials are meeting with her and when we have a taskforce under way. There is much consensus around the points that she raises. She has highlighted, quite rightly, the importance of HRT, and we have acted on that. Part of the reason for the delay until April is that the IT systems need to be put in place. I well recall, when I was a Treasury Minister, being asked to move at pace in response to covid, because of the cash-flow pressures on businesses, and sometimes having the same colleagues complaining that forward controls and other issues had not been put in place. We need to put the right IT in place. We will do that for April, and the work is under way. The issues that she raises are being addressed, but in an effective way.

As I said to the shadow Secretary of State, we will work with the royal colleges to address the issue of training. It is a perfectly fair point, and I do not think there is disagreement in the House on that. On the wider issue of addressing disparities, that is exactly what the taskforce is about. That is why we have such a relentless focus on data, why we have a women’s health ambassador to give greater voice to these issues, and why we have brought forward specific measures, such as the family hubs and mobile breast screening units, to better address those disparities.